A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.
Back
Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma
Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.
Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma
Episodes
All
All
Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.
Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.
Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5